Crystalline form of a PD-1/PD-L1 inhibitor

US11760756B2 · kind B2 · utility

Assignee

• Incyte Corporation · US

Inventors

• Zhongjiang Jia · Kennett Square, US
• Shili Chen · Cheshire, US
• Mei Li · Newark, US
• Pingli Liu · Wilmington, US
• Yongchun Pan · Wilmington, US
• Yongzhong Wu · Chadds Ford, US
• Jiacheng Zhou · Shanghai, CN

Key dates

• Filing date: Nov 5, 2021
• Grant date: Sep 19, 2023
• Expiry date: Dec 2, 2041

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07B2200/13
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

The present invention relates to crystalline forms of the PD-1/PD-L1 inhibitor (R)-1-((7-cyano-2-(3′-(3-(((R)-3-hydroxypyrrolidin-1-yl)methyl)-1,7-naphthyridin-8-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)pyrrolidine-3-carboxylic acid, including methods of preparation thereof, and related synthetic intermediates, where the compound is useful in the treatment of various diseases including infectious diseases and cancer.